COMPARE · Data as of August 12, 2026
EXEL vs GENB
Verdict: Side-by-side breakdown using the Bull Rankings model. EXEL scored 77.6, GENB scored 25.7 — EXEL leads.
Compare another set
EXEL
Exelixis, Inc.
77.6
$50.38 · $12.5B
fundamentals as of
Score gap
51.9
EXEL leads
GENB
Generate Biomedicines, Inc.
25.7
$15.09 · $1.9B
fundamentals as of
The model, pillar by pillar (0–100 each)
EXEL
stronger →← stronger
GENB
96
Qualityreturns · margins · balance sheet
34
86
Growthrevenue & earnings expansion
100
56
Valuevaluation vs sector peers
2
EXEL is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
EXEL
GENB
$1.2bC+
FCF
-$246mF
+9.2%B
Rev
+55.9%A
0.09B+
D/E
0.14B+
15.8xA-
P/E
—
2.56C
PEG
—
—
P/S
73.1xD
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
EXEL
GENB
43% below
Price vs fair valuelower is cheaper
—
~-5%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+53%
1-yr DCF upside
—
+76%
5-yr DCF upside
—
+116%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
EXEL
Why this score
- Buying back stock
- Durable high returns
GENB
Why this score
- Short track record
The companies
EXELExelixis, Inc.
Why now
Biotechnology · market cap $12.5b. 12% off the 52-week high of $57.57. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $52.94 (implying +5% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 47% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 136% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
GENBGenerate Biomedicines, Inc.
Why now
Biotechnology · market cap $1.9b. 17% off the 52-week high of $18.18. Revenue growing +56% — in hypergrowth territory. 5 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $25.60 (implying +70% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$246m) — capital raises or debt issuance likely required; dilution / leverage risk. P/S 73.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where EXEL and GENB diverge
On the headline score the gap is 51.9 points in favour of EXEL. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityEXEL 96.4 · GENB 33.9EXEL +62.5
- ValueEXEL 56.3 · GENB 2.3EXEL +54.0
- GrowthEXEL 86.0 · GENB 100.0GENB +14.0
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.